Filing Flows › Beta Bionics (BBNX) › Q1 2025
Beta Bionics (BBNX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Beta Bionics (BBNX) reported revenue of $17.6M for the first quarter 2025 (Q1 2025), +36% from a year earlier and -14% from the quarter before. Operating margin was -105.7%, net loss $28.7M (162.5% of revenue).
Beta Bionics, Q1 2025: revenue $17.6M (+36% year over year), operating margin -105.7%, net loss $28.7M, operating cash flow −$20.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.6M | -14% | +36% |
| Operating profit | −$18.6M | — | — |
| Net earnings | −$28.7M | — | — |
| Operating cash flow | −$20.0M | — | — |
What changed
Revenue was $17.6M in Q1 2025, up 36% year over year and down 14% from the previous quarter.
Gross margin was 50.9%, down 4.8 points from a year earlier. Operating costs exceeded revenue by $18.6M, an operating margin of -105.7%. Operating expenses grew 66% against revenue growth of 36%. The fastest-growing cost line was General & admin (+89%). The quarter ended with a net loss of $28.7M, wider than the previous quarter's $18.1M loss.
Operating cash flow was −$20.0M. Non-cash charges added back $303K of depreciation and $2.8M of share-based compensation. Working capital and other items added $5.6M. Capital expenditures of $333K exceeded it, leaving free cash flow of −$20.3M.
Questions
What was Beta Bionics' revenue in the first quarter 2025?
Beta Bionics (BBNX) reported revenue of $17.6M for the first quarter 2025 (Q1 2025), +36% from a year earlier and -14% from the quarter before.
Was Beta Bionics profitable in the first quarter 2025?
Operating loss was $18.6M (-105.7% of revenue) and net loss $28.7M.
Source: Beta Bionics 10-Q on SEC EDGAR.